PetVivo Holdings

PetVivo Holdings, Inc. is a veterinary biotech and biomedical device company. It is engaged in the business of translating or adapting human biotech and medical technology into products for commercialization in the veterinary market to treat companion animals such as dogs, horses, cats, and other animals suffering from osteoarthritis and other afflictions. The firm's lead product includes Kush, is an intra-articular injection comprised of patented, gel-like biomaterials that is being commercialized for companion animal osteoarthritis. The company was founded by John Lai and John F. Dolan on March 31, 2009 and is headquartered in Minneapolis, MN.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

PetVivo Holdings reports strong Q1 earnings, eyes market expansion

PetVivo Holdings demonstrated robust financial and operational progress in Q1 2025, driven by strong revenue growth and efficient cost management.
The company's focus on expanding market reach, accelerating Spryng adoption, and enhancing sales and marketing teams positions it for future growth.
While challenges like narrowing net loss persist, PetVivo's strategic initiatives and favorable financial position offer opportunities for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PetVivo Holdings, Inc. is a veterinary biotech and biomedical device company, which engages in the business of licensing and commercializing medical devices and biomaterials for the treatment and management of afflictions and diseases in animals, initially for dogs and horses. The firm's lead product includes Spryng with OsteoCushion Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses. The company was founded by John Lai and John F. Dolan on March 31, 2009 and is headquartered in Edina, MN.

MINNEAPOLIS, MN, US, April 25, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Mary Grace Rutland has accepted a position with the Company as its new Business Development Manager for the Mid-Atlantic Region of the United States.

Mary Grace Rutland Joins PetVivo Holdings, Inc. as the Mid-Atlantic Business Development Manager

MINNEAPOLIS, MN, US, April 14, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for companion animals and animal athletes is pleased to announce that Spencer Breithaupt has joined the Company's Board of Directors.

Spencer Breithaupt Joins PetVivo Holdings, Inc. Board of Directors

MINNEAPOLIS, MN, US, March 17, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that Erik Kleemam DVM, MPH, of Ethos Veterinary Health presented at the Veterinary Orthopedic Society (“VOS”) annual conference on the completion of the first cohort of dogs in a clinical study, which examined the benefit and tolerability of an intra-articular injection of a collagen-elastin biomaterial (i.e. Spryng™ with OsteoCuhsion™ Technology) into the stifle joint of dogs with suspected cruciate ligament rupture.

Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Big Sky, Montana

MINNEAPOLIS, MN, US, March 10, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced today it will be exhibiting at the Veterinary Orthopedic Society (“VOS”) annual conference to be held March 11th to Marth 18th, 2023 at the Yellowstone Conference Center in Big Sky, Montana.

PetVivo Holdings, Inc. to Exhibit and Dr. Erik Kleeman of Ethos Veterinary Health to Present Canine Study Results at the Veterinary Orthopedic Society Annual Conference

PetVivo Holdings, Inc. (NASDAQ:PETV ) Q3 2023 Earnings Conference Call February 9, 2023 5:00 PM ET Company Participants John Dolan - Chief Business Development Officer and General Counsel John Lai - President and CEO Bob Folkes - CFO Conference Call Participants John Dolan Greetings, and welcome to the PetVivo Holdings Third Quarter of Fiscal Year 2023 Financial Results Conference Call. My name is John Dolan, the Chief Business Development Officer and General Counsel at PetVivo.

PetVivo Holdings, Inc. (PETV) Q3 2023 Earnings Call Transcript

EDINA, MN , Feb. 09, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the third quarter of fiscal 2023. The Company began commercialization of its lead product Spryng™ with OsteoCushion™ Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses in September 2021.

PetVivo Reports Third Quarter of Fiscal 2023 Financial Results

MINNEAPOLIS, MN, US, Feb. 02, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Thursday, February 9, 2023 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day.

PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2022

MINNEAPOLIS, Jan. 26, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals today announced that the Company will be participating in the Lytham Partners Investor Select Conference taking place virtually on January 31, 2023.

PETVIVO HOLDINGS, INC. TO PARTICIPATE IN THE LYTHAM PARTNERS INVESTOR SELECT CONFERENCE

MINNEAPOLIS, Jan. 23, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals today announced it will be exhibiting at the 2023 Lake Tahoe Equine Conference from January 23rd to January 27th, 2023 at the Hyatt Lake Tahoe in Incline Village, Nevada.

PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE 44TH LAKE TAHOE EQUINE CONFERENCE IN INCLINE VILLAGE, NEVADA

MINNEAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals today announced it has entered into a lease agreement for approximately 14,000 sq. ft. of production and warehouse space located in Edina, Minnesota. This new facility will include multiple clean rooms for large-scale production of Spryng™ with OsteoCushion™ Technology, as well as other medical devices and therapeutics in the PetVivo product pipeline. The Company plans to move all of its production to this facility beginning in August 2023.

PETVIVO HOLDINGS, INC. ANNOUCES PLAN FOR NEW MANUFACTURING FACILITY

MINNEAPOLIS, MN, Dec. 28, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) (the "Company" or “PetVivo”) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, today announced that it has begun the application process to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex (“Horizon”) and MERJ Exchange Limited (“MERJ”).

PetVivo Holdings, Inc. Announces Application for Dual Listing on Upstream

MINNEAPOLIS, MN, Dec. 05, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced today hat it will be presenting virtually at the upcoming Sequire Virtual Small Cap Conference on Thursday, December 8th, at 2:30 PM EST. John Lai, Chief Executive Officer of PetVivo Holdings, Inc., will be giving the presentation.

PetVivo Holdings, Inc. to Present at Sequire Virtual Small Cap Conference on December 8th, 2022

PetVivo Holdings, Inc. (NASDAQ:PETV ) Q2 2023 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants John Dolan – Chief Business Development Officer and General Counsel John Lai – President and Chief Executive Officer Bob Folkes – Chief Financial Officer Conference Call Participants John Dolan All right. Let us begin the conference.

PetVivo Holdings, Inc. (PETV) Q2 2023 Earnings Call Transcript

Conference call begins at 4:00 p.m. Central time today

PetVivo Reports Second Quarter of Fiscal 2023 Financial Results

MINNEAPOLIS, MN, US, Nov. 03, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Thursday, November 10, 2022 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day.

PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR SECOND QUARTER ENDED September 30, 2022

Minneapolis, Minnesota--(Newsfile Corp. - October 20, 2022) - PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for companion animals, is pleased to announce today that it will be presenting at the 15th annual Main Event on Wednesday, October 26th at 08:00 AM to 8:25 AM PT at the Luxe Sunset Boulevard Hotel.

PetVivo Holdings, Inc. to Present at LD Micro Main Event XV

Minneapolis, Minnesota--(Newsfile Corp. - October 13, 2022) - PetVivo Holdings, Inc. (NASDAQ: PETV), ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for pets, will be participating in The ThinkEquity Conference, which will take place on October 26, 2022 at the Mandarin Oriental Hotel in New York. John F. Dolan will be presenting at 8:30 AM ET on October 26th.

PetVivo Holdings, Inc.: Invitation to The ThinkEquity Conference

MINNEAPOLIS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for equine athletes and companion animals, announced today that its signature product Spryng™ with OsteoCushion™ Technology is now available for purchase through MWI Animal Health, a subsidiary of AmerisourceBergen (“MWI”). MWI, a leading distributor of animal health products and services, has Spryng available for sale throughout the United States. Pursuant to an exclusive distribution agreement entered into by PetVivo and MWI, MWI will inventory, market, and promote Spryng throughout the United States.

PETVIVO HOLDING, INC. ANNOUNCES SPRYNG™ NOW AVAILABLE TO VETERNARIANS THROUGH MWI ANIMAL HEALTH

PetVivo Holdings, Inc. (NASDAQ:PETV ) Q1 2023 Results Conference Call August 11, 2022 5:00 PM ET Company Participants John Lai - Chief Executive Officer and President John Dolan - Chief Business Development Officer and General Counsel Robert Folkes - Chief Financial Officer Conference Call Participants Gary Zwetchkenbaum - Plum Tree Consulting LLC John Dolan Greetings, everyone. And welcome to the PetVivo Holdings First Quarter of Fiscal 2023 Financial Results Conference Call.

PetVivo Holdings, Inc. (PETV) CEO John Lai on Q1 2023 Results - Earnings Call Transcript

PetVivo Reports First Quarter of Fiscal 2023 Financial Results

MINNEAPOLIS, MN, US, Aug. 01, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for companion animals and animal athletes is pleased to announce that Rob Costantino and Leslie Coolidge have joined the Company's Board of Directors.

Leslie Coolidge and Rob Costantino Join PetVivo Holdings, Inc. Board of Directors

The market conditions aren't screaming “buy growth stocks now” at us but that doesn't mean all growth stocks, like PetVivo (OTCMKTS: PETV), are or will suffer the same afflictions. PetVivo caught our attention because of two things; its market and a new deal to market its lead therapy.

PetVivo Holdings Is A Growth Stock Worth a Look

PetVivo Holdings, Inc. (NASDAQ:PETV ) Q4 2022 Results Conference Call June 29, 2022 5:00 PM ET Company Participants John Lai - Chief Executive Officer and President John Dolan - Chief Business Development Officer and General Counsel Robert Folkes - Chief Financial Officer Conference Call Participants Gary Zwetchkenbaum - Plum Tree Consulting LLC John Lai John Dolan, can you start the introductions? John Dolan Yes.

PetVivo Holdings, Inc. (PETV) CEO John Lai on Q4 2022 Results - Earnings Call Transcript

PetVivo to Discuss Financial Results for the Fiscal Year End ended March 31, 2022 and Business Update

MINNEAPOLIS, June 29, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for equine athletes and companion animals, announced today it has entered into a definitive exclusive distribution services agreement with MWI Animal Health, a leading distributor of animal health products and services and a subsidiary of AmerisourceBergen.

News for PetVivo Holdings Stock (PETV)